Suraj Kalia

Adam Maeder

David Rescott

Ross Osborn

Jonathan Block

Jon Block

David Rescot

Edward White

Laura Roba

Michael Polark

Michael Pollock

Paige Chamberlain

- Nyxoah SA is expanding its commercial footprint in the **Middle East**.  **[1857190_0001104659-25-092730_tm2526703d1_ex99-1.htm:0]** 
- This expansion includes the establishment of new centers in **Dubai, Kuwait, and Abu Dhabi**.  **[1857190_0001104659-25-092730_tm2526703d1_ex99-1.htm:0]** 
- The expansion follows the **first successful Genio® implant in Abu Dhabi in September 2025**.  **[1857190_0001104659-25-092730_tm2526703d1_ex99-1.htm:0]** 
- The company's Genio system is designed to treat **moderate-to-severe Obstructive Sleep Apnea (OSA)**.  **[1857190_0001104659-25-092730_tm2526703d1_ex99-1.htm:0]**

Nyxoah Expands Middle East Presence

- Nyxoah announced the **pricing of an underwritten public offering** of its ordinary shares, with the offering expected to **close on September 23, 2025**.  **[1857190_0001104659-25-092526_tm2510209d2_ex99-2.htm:0]** 
- The company expects to receive **gross proceeds** of approximately **$[\u25cf] million** (EUR $[\u25cf] million) from the offering, before deducting underwriting discounts and commissions and other expenses, and excluding any exercise of the underwriters’ option to purchase additional shares.  **[1857190_0001104659-25-092526_tm2510209d2_ex99-2.htm:0]** 
- Nyxoah has granted the underwriters a **30-day option to purchase up to an additional $[\u25cf] ordinary shares** at the offering price.  **[1857190_0001104659-25-092526_tm2510209d2_ex99-2.htm:0]** 
- The **net proceeds** from the offering are intended for continued commercialization activities in the United States and other target markets, gathering clinical data, financing research and development for Genio system upgrades, building a pipeline of new technologies, and general corporate purposes including potential investments and acquisitions.  **[1857190_0001104659-25-092526_tm2510209d2_ex99-2.htm:0]** **[1857190_0001104659-25-092526_tm2510209d2_ex99-1.htm:0]**

Nyxoah Announces Pricing of Public Offering

- Nyxoah SA announced on **September 15, 2025**, that it has filed a **patent infringement lawsuit** against **Inspire Medical Systems, Inc.**  **[1857190_0001104659-25-090018_tm2526060d1_6k.htm:0]** **[1857190_0001104659-25-090018_tm2526060d1_ex99-1.htm:0]** 
- The lawsuit alleges that Inspire's **IV and V devices infringe three U.S. Patents** held by Nyxoah: **Nos. 8,700,183, 9,415,215, and 9,415,216**.  **[1857190_0001104659-25-090018_tm2526060d1_6k.htm:0]** **[1857190_0001104659-25-090018_tm2526060d1_ex99-1.htm:0]** 
- The suit was filed in the **United States District Court for the District of Delaware**, seeking **injunctive relief and damages** for the alleged infringement.  **[1857190_0001104659-25-090018_tm2526060d1_6k.htm:0]** **[1857190_0001104659-25-090018_tm2526060d1_ex99-1.htm:0]**

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems

Nyxoah (NYXH)